4-((4-(bromomethyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione | 1323408-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4-((4-(bromomethyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
• 英文别名: 4-[[4-(Bromomethyl)phenyl]methoxy]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
• CAS: 1323408-40-7
• 化学式: C₂₁H₁₇BrN₂O₅
• 分子量: 457.28
• InChiKey: GQTBDUOHRFCOON-UHFFFAOYSA-N

物化性质

• 沸点：
  680.5±55.0 °C(Predicted)
• 密度：
  1.599±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  92.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-异丙基哌啶 、 4-((4-(bromomethyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 以 乙腈 为溶剂， 以80%的产率得到2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((4-((4-ISOPROPYLPIPERIDIN-1-YL)METHYL)BENZYL)OXY)ISOINDOLINE-1,3-DIONE
  参考文献：
  名称：

  Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same

  摘要：

  提供了4'-芳基甲氧基异吲哚啉化合物，以及其药用盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。

  公开号：

  US20110196150A1
• 作为产物：
  描述：

  4-(叔丁基二甲基甲硅烷基氧基甲基)苄醇 在 N-溴代丁二酰亚胺(NBS) 、 二甲基硫 、 硫酸 、 三溴化磷 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 39.83h， 生成 4-((4-(bromomethyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

  摘要：

  Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

  DOI：

  10.1021/acs.jmedchem.9b01928

文献信息

• ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：Celgene Corporation

  公开号：US20180037567A1

  公开（公告）日：2018-02-08

  Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了4'-芳基甲氧基异吲哚啉化合物及其药学上可接受的盐、溶剂合物、笼合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。
• Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
  申请人：Celgene Corporation

  公开号：US10189814B2

  公开（公告）日：2019-01-29

  Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明提供了 4′-芳基甲氧基异吲哚啉化合物及其药学上可接受的盐、溶液剂、凝胶体、立体异构体和原药。还公开了这些化合物的使用方法和药物组合物。
• GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF
  申请人：Shanghaitech University

  公开号：EP4112614A1

  公开（公告）日：2023-01-04

  The present disclosure relates to glutarimide skeleton-based compounds of Formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, and uses thereof. The present disclosure further relates to a pharmaceutical composition comprising, as an active ingredient, the glutarimide skeleton-based compounds of Formula (I), or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and/or treat a tumor.

  本公开涉及式(I)的戊二酰亚胺骨架的化合物或其盐、对映异构体、立体异构体、溶剂合物或多晶型，及其用途。本公开进一步涉及包含式(I)的戊二酰亚胺骨架的化合物或其盐、对映异构体、立体异构体、溶剂合物或多晶型作为活性成分的药物组合物，及其用途。在本公开中设计和合成的这些系列化合物能够有效预防和/或治疗肿瘤。
• US8518972B2
  申请人：——

  公开号：US8518972B2

  公开（公告）日：2013-08-27
• US9309219B2
  申请人：——

  公开号：US9309219B2

  公开（公告）日：2016-04-12